Mitra® and hemaPEN® receive regulatory certification as medical devices for remote blood sample col...
Highlights: * Expanded participation in ATH434 Phase 2 clinical trial with sites opened for recr...
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Austral...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...
- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkin...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...
MELBOURNE, Australia and SAN FRANCISCO , Oct. 26, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ...
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Austral...
- Wearable sensors strongly correlated with clinical scales on motor impairment - - bioMUSE Study ...
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia...
Second region now open for enrolment for rare, rapidly progressive, neurodegenerative disease MELB...
* Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins * Reg...
MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: A...
Highlights * Trajan to acquire Chromatography Research Supplies, Inc. (CRS), a leading global ma...
Multiple System Atrophy is a rare, rapidly progressive, neurodegenerative disease that causes profo...
MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)...
* The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia ...
MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: A...